AN EXPLORATORY, OPEN LABELLED, PHASE IIA STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF INCREMENTAL DOSES OF MGB-BP-3 IN PATIENTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD)

Registry ID

MGB-BP-3-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

MGB BIOPHARMA LIMITED

Start date

2019-05-10

Last update

2019-01-08

Conditions

• CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHOEA (CDAD)

Related clinical trials

• A PROSPECTIVE, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF CADAZOLID VERSUS VANCOMYCIN IN PEDIATRIC SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA
• A PHASE 2B, PARALLEL-GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF SYN-004 COMPARED TO PLACEBO FOR THE PREVENTION OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA IN PATIENTS WITH A DIAGNOSIS OF LOWER RESPIRATORY TRACT INFECTION

View on source registry